RETRACTED ARTICLE: Toll-like receptor 9 agonist IMO cooperates with everolimus in renal cell carcinoma by interfering with tumour growth and angiogenesis
V. Damiano(University of Naples Federico II), Giampaolo Tortora(University of Naples Federico II)
Cited by 18
Related Papers
Maintenance Olaparib for Germline <i>BRCA</i> -Mutated Metastatic Pancreatic Cancer
|New England Journal of Medicine|2019|2.2k
Exome sequencing identifies frequent inactivating mutations in BAP1, ARID1A and PBRM1 in intrahepatic cholangiocarcinomas
|Nature Genetics|2013|709
Upfront FOLFOXIRI plus bevacizumab with or without atezolizumab in the treatment of patients with metastatic colorectal cancer (AtezoTRIBE): a multicentre, open-label, randomised, controlled, phase 2 trial
|The Lancet Oncology|2022|268
Overall Survival Results From the POLO Trial: A Phase III Study of Active Maintenance Olaparib Versus Placebo for Germline BRCA-Mutated Metastatic Pancreatic Cancer
|Journal of Clinical Oncology|2022|224
Nivolumab plus Ipilimumab in Microsatellite-Instability–High Metastatic Colorectal Cancer
|New England Journal of Medicine|2024|208